M&A Deal Summary

Kiadis Pharma Acquires Celmed BioSciences

On December 11, 2006, Kiadis Pharma acquired life science company Celmed BioSciences

Acquisition Highlights
  • This is Kiadis Pharma’s 1st transaction in the Life Science sector.
  • This is Kiadis Pharma’s 1st transaction in Canada.

M&A Deal Summary
Date 2006-12-11
Target Celmed BioSciences
Sector Life Science
Buyer(s) Kiadis Pharma
Deal Type Add-on Acquisition

Target

Celmed BioSciences

Saint-Laurent, Canada
Celmed develops photodynamic-based therapies to treat hematological and immune diseases using its proprietary technology Theralux(TM).

Search 192,349 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Kiadis Pharma

Amsterdam, Netherlands

website

Category Company
Sector Life Science
DESCRIPTION

Kiadis Pharma is a clinical stage biopharmaceutical company pioneering a proprietary cell-based, personalized therapy for patients with blood cancers and related disorders, an area of significant unmet medical need.Kiadis Pharma’s unique and powerful platform technology has led to an initial experimental product, ATIR™, which has already been clinically tested on sixty patients. Kiadis Pharma is based in Amsterdam, Netherlands.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Canada) 1 of 1
Year (2006) 1 of 1
Mergr

Product

Company

Legal